Dr. Rubenstein is an internationally-prominent endocrinologist recognized for clinical expertise and groundbreaking research in diabetes. Well-known for his inspired teaching, Dr. Rubenstein has served in numerous professional leadership positions during his career. These include President of the Association of Professors of Medicine; President of the Association of American Physicians; President of the Central Society for Clinical Research; Chairman of the American Board of Internal Medicine; Chairman of the Board of the Association of Academic Health Centers; and Chair of the National Diabetes Advisory Board. He has been a member of a study section and of the Advisory Council of the National Institute of Diabetes and Digestive and Kidney Diseases.
Michael Miller, MD
Dr. Miller was the Medical Director of the Diabetes Center of what is now the University of Michigan Health Systems, MidMichigan Campus, for approximately 35 years. He is Board Certified in Diabetes and Endocrinology and Internal Medicine. He is a lifetime member of the ADA and AACE, and was one of the first group of diabetes practitioners granted the status of Certified Diabetes Technology Clinician(CDTC). His clinical practice focused on advanced diabetes management.
Clyde Shearman, PhD
Dr. Shearman is a Research and Development Executive with over 35 years of industry experience in the areas of molecular biology, immunology, oncology and endocrinology. He received a B.A. in Biology from the University of Virginia and a Ph.D. in Biochemistry from Thomas Jefferson University and Medical College. Before joining Glycadia, he was Research Director in Molecular Biology at Sterling Winthrop, Inc., a Group Leader in Protein Engineering at Genzyme Corporation, and a Senior Scientist in Molecular Biology at Centocor, Inc. He has over 60 scientific publications and 14 patent applications.
Van-Yu Wu, PhD
Dr. Wu is a highly published protein chemist and biologist. Previously, Dr. Wu was Senior Research Associate at the University of Medicine and Dentistry of New Jersey and at Wayne State University School of Medicine in Detroit, Michigan. Dr. Wu received his B.S. from the University of Taiwan, an M.S. from the University of Detroit and a Ph.D. from Wayne State University. He has been a research investigator for the National Kidney Foundation and Principal Investigator for research sponsored by the NIH.
Dr. John Brennan
Dr. Brennan is an accomplished pharma industry research and development scientist with over 35 years experience in all stages of endocrine, renal and respiratory drug development, regulatory affairs and lifecycle management. He directed multi-function global asset development teams and worked in bioanalytical assay development, drug metabolism and pharmacokinetics, clinical pharmacology, Phase I-IV clinical trials and global project management. He has also served as primary point-of-contact for pipeline governance, therapeutic area executive committees and external alliance partners. Dr. Brennan is a graduate of Temple University and received his Ph.D. in Pharmaceutical Sciences from The Philadelphia College of Pharmacy and Science. Before joining Glycadia he was a Senior Project Leader at AbbVie in the General Medicine Therapeutic Area, a Global Clinical Director in the Men’s Health and Women’s Health Therapeutic Area at Solvay Pharma, an Associate Medical Director in Clinical Pharmacology at Bristol-Myers Squibb. He has over 50 scientific publications and 2 patent applications.
Sarabjit S. Ashta
Sarabjit brings more than 20 years’ experience in the pharmaceutical industry and a proven record of success in growing businesses through external partnerships, in-licensing and M&A. Prior to joining Glycadia, he held leadership roles at Dr. Reddy’s Laboratories, Endo Pharmaceuticals, Biogen and Becton Dickinson which enabled him to create value-enhancing opportunities across a broad spectrum, including biopharmaceuticals, specialty pharmaceuticals, generics, medical devices and diagnostics. Sarabjit received his undergraduate degree in Econometrics from the London School of Economics and an MBA in International Finance from NYU Stearn School of Business.